Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial
复制标题
DOI：
10.1016/s0140-6736(18)32752-1
复制
发表时间：
2019-01-05
期刊：
影响因子：
168.9
通讯作者：
Dunn, Janet
中科院分区：
文献类型：
--
作者：
Mehanna, Hisham;Robinson, Max;Dunn, Janet
背景：人乳头瘤病毒（HPV）阳性口咽癌的发病率正在迅速增加，这种疾病影响年轻患者。西妥昔单抗，一种表皮生长因子受体抑制剂，已被提议用于治疗降级，在这种情况下，以减少标准顺铂治疗的毒性，但没有随机证据存在的有效性，这种strategy.Methods我们做了一个开放标签随机对照3期试验，在32个头部和颈部治疗中心在爱尔兰，荷兰和英国，在18岁或18岁以上的HPV阳性低风险口咽癌患者中（非吸烟者或有吸烟史的终生吸烟者，
Background The incidence of human papillomavirus (HPV)-positive oropharyngeal cancer, a disease affecting younger patients, is rapidly increasing. Cetuximab, an epidermal growth factor receptor inhibitor, has been proposed for treatment de-escalation in this setting to reduce the toxicity of standard cisplatin treatment, but no randomised evidence exists for the efficacy of this strategy.Methods We did an open-label randomised controlled phase 3 trial at 32 head and neck treatment centres in Ireland, the Netherlands, and the UK, in patients aged 18 years or older with HPV-positive low-risk oropharyngeal cancer (non-smokers or lifetime smokers with a smoking history of